Pituitary Apoplexy

Introduction:
Classical pituitary apoplexy is a medical emergency and rapid replacement with hydrocortisone maybe life saving. It is caused by haemorrhage and/or infarction of a tumour within the pituitary gland. A high index of clinical suspicion is essential to diagnose this condition as prompt management may be life and vision saving. This guideline aims to take the non-specialist through the initial phase of assessment and management.

Clinical presentation:

- A diagnosis of pituitary apoplexy should be considered in all patients who have acute severe headache and any of the following:
  - patients in whom subarachnoid haemorrhage (SAH) & meningitis have been excluded
  - patients with neuro-ophthalmic signs
  - patients with pre-existing pituitary tumours.
- Acute severe headache is the most common & earliest manifestation. Headache may be accompanied by nausea and vomiting
- Ocular palsies, most commonly a third nerve palsy, can occur due to involvement of the cavernous sinus
- Reduced visual acuity and visual field defects, most commonly a bi-temporal hemianopia, are due to optic chiasmal compression
- Fever, neck stiffness, photophobia or reduced consciousness (similar to signs/symptoms of SAH or meningitis) may occur.

Precipitating factors:
Hypertension, major surgery, especially coronary artery bypass grafting, dynamic testing of the pituitary gland, anticoagulation therapy, coagulopathies, pregnancy and head trauma.

Differential diagnosis:
- SAH due to ruptured intracranial aneurysm or arteriovenous malformation
- Bacterial/Viral meningitis
- Brainstem infarction
- Cavernous sinus thrombosis

Management:
- Ensure haemodynamic stability through supportive measures
- Urgent bloods – urea & electrolytes, full blood count, renal and liver function tests, clotting profile
- Indications for empirical steroid therapy in patients with pituitary apoplexy are haemodynamic instability, altered consciousness level, reduced visual acuity and severe visual field defects. Steroid replacement is potentially life-saving in these patients
- In adults hydrocortisone 100mg IM bolus followed by 50-100mg six hourly by intramuscular injection or 100-200 mg as an intravenous bolus followed by 2-4 mg per hour by continuous iv infusion can be used.
Emergency Endocrine Guidance

- Careful assessment of fluid & electrolyte balance
- Ideally, endocrine evaluation with blood samples for random serum cortisol, TSH, free T4, prolactin, IGF-1, LH, FSH, testosterone (men), oestradiol (women) for later analysis
- Bedside assessment of visual acuity and fields
- Further neuro-ophthalmic assessments can be undertaken when the patient is clinically stable
- CT Brain (+/- LP) to exclude SAH and meningitis should be undertaken if not already done
- Magnetic resonance imaging (MRI) is the investigation of choice and has been shown to confirm the diagnosis in over 90% of patients. A pituitary CT is indicated if MRI is contraindicated or not possible.
- Urgent referral to the joint neurosurgical/endocrine unit for definitive management

After emergency care - Where should patients with pituitary apoplexy be managed?
Once the diagnosis has been confirmed, it is recommended that all patients be transferred once medically stabilised following liaison and advice from the specialist neurosurgical/endocrine team to the local neurosurgical/endocrine team as soon as possible. Neurosurgical high dependency unit (HDU) facilities must be available. This team must have access to specialist endocrine and ophthalmological expertise. These patients should then be managed according the National guidelines for pituitary apoplexy [http://www.endocrinology.org/policy/docs/11-01_PituitaryApoplexy.pdf](http://www.endocrinology.org/policy/docs/11-01_PituitaryApoplexy.pdf)

Indications for surgery:
Patients should first be stabilised medically with steroid replacement if needed before surgical intervention. Studies have shown significantly greater improvement in visual acuity and visual field defects in patients who had early surgery (within 8 days).
Surgical intervention should be considered in patients with
- Severely reduced visual acuity
- Severe and persistent visual field defects
- Deteriorating level of consciousness

Long term follow up:
All patients with pituitary apoplexy need follow up by endocrine and neurosurgical teams. They require repeat assessment of pituitary and visual function, at ~4–6 weeks. Thereafter, 6-12 monthly follow up to optimise hormonal replacement and to monitor tumour progression/recurrence.

Summary:
Pituitary apoplexy is a rare and potentially lethal endocrine emergency, characterised by acute severe headache, visual defects, and/or reduced consciousness. The clinical presentation often mimics other more common neurological emergencies Prompt resuscitation and corticosteroid replacement may be life saving
MRI scan is the investigation of choice
Urgent discussion with the regional neurosurgical/endocrine team is essential
Surgical intervention should be considered in patients with severe and persisting visual defects or in those with deteriorating level of consciousness after medical stabilisation and steroid replacement
Suspected pituitary apoplexy

- Supportive measures to ensure haemodynamic stability
- Assessment and management of fluid/electrolyte balance
- Consider hydrocortisone replacement

- Urgent biochemical and endocrine assessment (FBC, U and E, LFT, clotting screen, IGF1, GH, PRL, TSH, T4, LH, FSH, cortisol, testosterone or oestradiol)

- Urgent MRI to confirm diagnosis
  or
- A dedicated pituitary CT scan if MRI is contraindicated

- Liaise with regional endocrine and neurosurgical team immediately after the diagnosis is confirmed

- Severely reduced visual acuity
- Severe and persistent or deteriorating visual field defects
- Deteriorating level of consciousness

  Yes  
  Consider surgical management

  No  
  Conservative management
  Close monitoring (Neurological, visual and endocrine)

Patient stable or improving

  Yes  
  Continue conservative management

  No  
  Consider surgical management

References:

This information is provided by the Society for Endocrinology's Clinical Committee, February 2013, and will be reviewed annually.